Journal article
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn’s disease—the devil is in the detail
A Srinivasan, P De Cruz, DR van Langenberg
Alimentary Pharmacology and Therapeutics | WILEY | Published : 2020
DOI: 10.1111/apt.15862
Abstract
LINKED CONTENTThis article is linked to Alric et al papers. To view these articles, visit https://doi.org/10.1111/apt.15706 and https://doi.org/10.1111/apt.15888.
Grants
Funding Acknowledgements
PDC is supported by a National Health & Medical Research Council (NH&MRC) Early Career Fellowship. AS is supported by an Australian Government Research Training Program (RTP) scholarship.